Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis | MicrobiomeTrials← Back to trialsNCT04799288
Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2021-09-24Est. Completion: 2027-12-31
Enrollment target: 24 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
HTLV-I InfectionTropical Spastic Paraparesis
Objective:
Human T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) is a rare n…
Bethesda, United States
HTLV-I-Associated Myelopathy
An open-label, non-randomised, uncontrolled, proof-of-concept study of patients with HTLV-I-associated myelopathy/Tropic…
Kanagawa, JapanCompleted Oct 2011